Advances in Alzheimer’s Disease-Associated Aβ Therapy Based on Peptide
Abstract
:1. Introduction
2. Design of Chiral Amino Acid- or Chiral Peptide-Based Inhibitors
3. Design of Peptide through Phage Display
4. Design of Peptides Based on the Core Sequence of Aβ Fibrosis
5. Computer-Aided Peptide Inhibitors Based on the Segments and Structure of Aβ
6. Conclusions and Future Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement. 2023, 19, 1598–1695. [Google Scholar] [CrossRef] [PubMed]
- Wong, W. Economic burden of Alzheimer disease and managed care considerations. Am. J. Manag. Care 2020, 26, S177–S183. [Google Scholar]
- Alzheimer’s Disease International. World Alzheimer Report 2018; Alzheimer’s Disease International: London, UK, 2018. [Google Scholar]
- Zvěřová, M. Clinical aspects of Alzheimer’s disease. Clin. Biochem. 2019, 72, 3–6. [Google Scholar] [CrossRef] [PubMed]
- Sirkis, D.W.; Bonham, L.W.; Johnson, T.P.; Joie, R.L.; Yokoyama, J.S. Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease. Mol. Psychiatry 2022, 27, 2674–2688. [Google Scholar] [CrossRef] [PubMed]
- Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer’s disease. Nat. Rev. Dis. Primers 2021, 7, 33. [Google Scholar] [CrossRef]
- Ichimata, S.; Martinez-Valbuena, I.; Lee, S.; Li, J.; Karakani, A.M.; Kovacs, G.G. Distinct molecular signatures of amyloid-beta and tau in Alzheimer’s disease associated with down syndrome. Int. J. Mol. Sci. 2023, 24, 11596. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Chen, W.-D.; Wang, Y.-D. β-Amyloid: The key peptide in the pathogenesis of Alzheimer’s disease. Front. Pharmacol. 2015, 6, 221. [Google Scholar] [CrossRef]
- Cheng, Y.; Tian, D.-Y.; Wang, Y.-J. Peripheral clearance of brain-derived Aβ in Alzheimer’s disease: Pathophysiology and therapeutic perspectives. Transl. Neurodegener. 2020, 9, 16. [Google Scholar] [CrossRef]
- Cummings, J.; Feldman, H.H.; Scheltens, P. The “rights” of precision drug development for Alzheimer’s disease. Alzheimer’s Res. Ther. 2019, 11, 76. [Google Scholar] [CrossRef]
- Liu, Y.-H.; Giunta, B.; Zhou, H.-D.; Tan, J.; Wang, Y.-J. Immunotherapy for Alzheimer disease—The challenge of adverse effects. Nat. Rev. Neurol. 2012, 8, 465–469. [Google Scholar] [CrossRef]
- Berchtold, N.C.; Cotman, C.W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol. Aging 1998, 19, 173–189. [Google Scholar] [CrossRef] [PubMed]
- Aillaud, I.; Funke, S.A. Tau aggregation inhibiting peptides as potential therapeutics for Alzheimer’s disease. Cell Mol. Neurobiol. 2023, 43, 951–961. [Google Scholar] [CrossRef] [PubMed]
- Karlawish, J.; Grill, J.D. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nat. Rev. Neurol. 2021, 17, 523–524. [Google Scholar] [CrossRef] [PubMed]
- De Castro, N.; Braun, J.; Charreau, I.; Lafeuillade, A.; Viard, J.-P.; Allavena, C.; Aboulker, J.-P.; Molina, J.-M.; The EASIER ANRS 138 Study Group. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: A sub-study of the ANRS-138 EASIER trial. AIDS Res. Ther. 2016, 13, 17. [Google Scholar] [CrossRef]
- Bourinet, E.; Zamponi, G.W. Block of voltage-gated calcium channels by peptide toxins. Neuropharmacology 2017, 127, 109–115. [Google Scholar] [CrossRef]
- Deer, T.R.; Pope, J.E.; Hanes, M.C.; McDowell, G.C. Intrathecal therapy for chronic pain: A review of morphine and ziconotide as firstline options. Pain Med. 2019, 20, 784–798. [Google Scholar] [CrossRef]
- Fisher, E.; Pavlenko, K.; Vlasov, A.; Ramenskaya, G. Peptide-based therapeutics for oncology. Pharm. Med. 2019, 33, 9–20. [Google Scholar] [CrossRef]
- Iyengar, S.; Ossipov, M.H.; Johnson, K.W. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 2017, 158, 543–559. [Google Scholar] [CrossRef]
- Sloan, L.A. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. J. Diabetes 2019, 11, 938–948. [Google Scholar] [CrossRef]
- Peterson, S.C.; Barry, A.R. Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: A meta-analysis. Curr. Diabetes Rev. 2018, 14, 273–279. [Google Scholar] [CrossRef]
- Torres, M.D.T.; Sothiselvam, S.; Lu, T.K.; de la Fuente-Nunez, C. Peptide design principles for antimicrobial applications. J. Mol. Biol. 2019, 431, 3547–3567. [Google Scholar] [CrossRef]
- Lee, A.C.; Harris, J.L.; Khanna, K.K.; Hong, J.H. A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci. 2019, 20, 2383. [Google Scholar] [CrossRef] [PubMed]
- Henninot, A.; Collins, J.C.; Nuss, J.M. The current state of peptide drug discovery: Back to the future? J. Med. Chem. 2018, 61, 1382–1414. [Google Scholar] [CrossRef] [PubMed]
- Sidorova, A.; Bystrov, V.; Lutsenko, A.; Shpigun, D.; Belova, E.; Likhachev, I. Quantitative assessment of chirality of protein secondary structures and phenylalanine peptide nanotubes. Nanomaterials 2021, 11, 3299. [Google Scholar] [CrossRef] [PubMed]
- Pisarewicz, K.; Mora, D.; Pflueger, F.C.; Fields, G.B.; Marí, F. Polypeptide chains containing d-γ-hydroxyvaline. J. Am. Chem. Soc. 2005, 127, 6207–6215. [Google Scholar] [CrossRef] [PubMed]
- Nakanishi, T.; Yamakawa, N.; Asahi, T.; Shibata, N.; Ohtani, B.; Osaka, T. Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality. Chirality 2004, 16, S36–S39. [Google Scholar] [CrossRef]
- Schapira, A.H.V.; Emre, M.; Jenner, P.; Poewe, W. Levodopa in the treatment of Parkinson’s disease. Eur. J. Neurol. 2009, 16, 982–989. [Google Scholar] [CrossRef]
- Ulijn, R.V.; Smith, A.M. Designing peptide based nanomaterials. Chem. Soc. Rev. 2008, 37, 664–675. [Google Scholar] [CrossRef]
- Liu, G.; Zhu, L.; Ji, W.; Feng, C.; Wei, Z. Inversion of the supramolecular chirality of nanofibrous structures through co-assembly with achiral molecules. Angew. Chem. Int. Ed. 2016, 55, 2411–2415. [Google Scholar] [CrossRef]
- Smith, D.K. Lost in translation? Chirality effects in the self-assembly of nanostructured gel-phase materials. Chem. Soc. Rev. 2009, 38, 684–694. [Google Scholar] [CrossRef]
- Qing, G.; Zhao, S.; Xiong, Y.; Lv, Z.; Jiang, F.; Liu, Y.; Chen, H.; Zhang, M.; Sun, T. Chiral effect at protein/graphene interface: A bioinspired perspective to understand amyloid formation. J. Am. Chem. Soc. 2014, 136, 10736–10742. [Google Scholar] [CrossRef] [PubMed]
- Xue, C.; Lin, T.Y.; Chang, D.; Guo, Z. Thioflavin T as an amyloid dye: Fibril quantification, optimal concentration and effect on aggregation. R. Soc. Open Sci. 2017, 4, 160696. [Google Scholar] [CrossRef] [PubMed]
- Drolle, E.; Hane, F.; Lee, B.; Leonenko, Z. Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer’s disease. Drug Metab. Rev. 2014, 46, 207–223. [Google Scholar] [CrossRef] [PubMed]
- Gong, S.; Liu, J.; Tian, M.; Wang, K.; Cai, S.; Wang, W.; Shen, L. Unravelling the mechanism of amyloid-beta peptide oligomerization and fibrillation at chiral interfaces. Chem. Commun. 2019, 55, 13725–13728. [Google Scholar] [CrossRef]
- Rhule, J.T.; Hill, C.L.; Judd, D.A. Polyoxometalates in medicine. Chem. Rev. 1998, 98, 327–357. [Google Scholar] [CrossRef]
- Hasenknopf, B.; Micoine, K.; Lacôte, E.; Thorimbert, S.; Malacria, M.; Thouvenot, R. Chirality in polyoxometalate chemistry. Eur. J. Inorg. Chem. 2008, 32, 5001–5013. [Google Scholar] [CrossRef]
- Gao, N.; Du, Z.; Guan, Y.; Dong, K.; Ren, J.; Qu, X. Chirality-selected chemical modulation of amyloid aggregation. J. Am. Chem. Soc. 2019, 141, 6915–6921. [Google Scholar] [CrossRef]
- Javed, I.; Peng, G.; Xing, Y.; Yu, T.; Zhao, M.; Kakinen, A.; Faridi, A.; Parish, C.L.; Ding, F.; Davis, T.P.; et al. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nat. Commun. 2019, 10, 3780. [Google Scholar] [CrossRef]
- Liu, P.; Chen, G.; Zhang, J. A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Molecules 2022, 27, 1372. [Google Scholar] [CrossRef]
- Wang, X.; Wang, C.; Chu, H.; Qin, H.; Wang, D.; Xu, F.; Ai, X.; Quan, C.; Li, G.; Qing, G. Molecular chirality mediated amyloid formation on phospholipid surfaces. Chem. Sci. 2020, 11, 7369–7378. [Google Scholar] [CrossRef]
- Hou, K.; Zhao, J.; Wang, H.; Li, B.; Li, K.; Shi, X.; Wan, K.; Ai, J.; Lv, J.; Wang, D.; et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease. Nat. Commun. 2020, 11, 4790. [Google Scholar] [CrossRef] [PubMed]
- Xu, P.; Ghosh, S.; Gul, A.R.; Bhamore, J.R.; Park, J.P.; Park, T.J. Screening of specific binding peptides using phage-display techniques and their biosensing applications. TrAC Trend Anal. Chem. 2021, 137, 116229. [Google Scholar] [CrossRef]
- Nixon, A.E.; Sexton, D.J.; Ladner, R.C. Drugs derived from phage display: From candidate identification to clinical practice. mAbs 2014, 6, 73–85. [Google Scholar] [CrossRef] [PubMed]
- Yang, T.; Zhang, X.; Zhang, X.; Chen, M.; Wang, J. Chromium(III) binding phage screening for the selective adsorption of Cr(III) and chromium speciation. ACS Appl. Mater. Interfaces 2015, 7, 21287–21294. [Google Scholar] [CrossRef]
- Yang, T.; Zhang, X.; Yang, J.; Wang, Y.; Chen, M. Screening arsenic(III)-binding peptide for colorimetric detection of arsenic(III) based on the peptide induced aggregation of gold nanoparticles. Talanta 2018, 177, 212–216. [Google Scholar] [CrossRef]
- Das, S.; Devireddy, R.; Gartia, M.R. Surface plasmon resonance (SPR) sensor for cancer biomarker detection. Biosensors 2023, 13, 396. [Google Scholar] [CrossRef]
- Yu, H.; Zhao, Q. DNAzyme-based microscale thermophoresis sensor. Anal. Chem. 2023, 95, 2152–2156. [Google Scholar] [CrossRef]
- Pohanka, M. Quartz crystal microbalance biosensor for the detection of procalcitonin. Talanta 2023, 257, 124325. [Google Scholar] [CrossRef]
- Orner, B.P.; Liu, L.; Murphy, R.M.; Kiessling, L.L. Phage display affords peptides that modulate beta-amyloid aggregation. J. Am. Chem. Soc. 2006, 128, 11882–11889. [Google Scholar] [CrossRef]
- Zhang, X.; Zhang, X.; Li, Y.; Zhong, M.; Zhao, P.; Guo, C.; Xu, H.; Wang, T.; Gao, H. Brain targeting and Aβ binding bifunctional nanoparticles inhibit amyloid protein aggregation in APP/PS1 transgenic mice. ACS Chem. Neurosci. 2021, 12, 2110–2121. [Google Scholar] [CrossRef]
- Vorhees, C.V.; Williams, M.T. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1, 848–858. [Google Scholar] [CrossRef] [PubMed]
- Wang, F.; Zhou, X.-L.; Yang, Q.-G.; Xu, W.-H.; Wang, F.; Chen, Y.-P.; Chen, G.-H. A peptide that binds specifically to the β-amyloid of Alzheimer’s disease: Selection and assessment of anti-β-amyloid neurotoxic effects. PLoS ONE 2011, 6, e27649. [Google Scholar] [CrossRef] [PubMed]
- Wiesehan, K.; Willbold, D. Mirror-image phage display: Aiming at the mirror. ChemBioChem 2003, 4, 811–815. [Google Scholar] [CrossRef] [PubMed]
- Schumacher, T.N.; Mayr, L.M.; Minor, D.L., Jr.; Milhollen, M.A.; Burgess, M.W.; Kim, P.S. Identification of d-peptide ligands through mirrorimage phage display. Science 1996, 271, 1854–1857. [Google Scholar] [CrossRef] [PubMed]
- Funke, S.A.; Willbold, D. Mirror image phage display—A method to generate d-peptide ligands for use in diagnostic or therapeutical applications. Mol. Biosyst. 2009, 5, 783–786. [Google Scholar] [CrossRef] [PubMed]
- Van Groen, T.; Wiesehan, K.; Funke, S.A.; Kadish, I.; Nagel-Steger, L.; Willbold, D. Reduction of Alzheimer’s disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. Chem. Med. Chem. 2008, 3, 1848–1852. [Google Scholar] [CrossRef]
- Funke, S.A.; van Groen, T.; Kadish, I.; Bartnik, D.; Nagel-Steger, L.; Brener, O.; Sehl, T.; Batra-Safferling, R.; Moriscot, C.; Schoehn, G.; et al. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer’s Disease transgenic mice. ACS Chem. Neurosci. 2010, 1, 639–648. [Google Scholar] [CrossRef]
- Brener, O.; Dunkelmann, T.; Gremer, L.; van Groen, T.; Mirecka, E.A.; Kadish, I.; Willuweit, A.; Kutzsche, J.; Jurgens, D.; Rudolph, S.; et al. QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers. Sci. Rep. 2015, 5, 13222. [Google Scholar] [CrossRef]
- Ziehm, T.; Brener, O.; van Groen, T.; Kadish, I.; Frenzel, D.; Tusche, M.; Kutzsche, J.; Reiss, K.; Gremer, L.; Nagel-Steger, L.; et al. Increase of positive net charge and conformational rigidity enhances the efficacy of d-enantiomeric peptides designed to eliminate cytotoxic abeta species. ACS Chem. Neurosci. 2016, 7, 1088–1096. [Google Scholar] [CrossRef]
- Jiang, N.; Frenzel, D.; Schartmann, E.; van Groen, T.; Kadish, I.; Shah, N.J.; Langen, K.-J.; Willbold, D.; Willuweit, A. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide. Biochim. Biophys. Acta BBA Biomembr. 2016, 1858, 2717–2724. [Google Scholar] [CrossRef]
- Tjernberg, L.O.; Naslund, J.; Lindqvist, F.; Johansson, J.; Karlstrom, A.R.; Thyberg, J.; Terenius, L.; Nordstedt, C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271, 8545–8548. [Google Scholar] [CrossRef] [PubMed]
- Hao, S.; Li, X.; Han, A.; Yang, Y.; Fang, G.; Liu, J.; Wang, S. CLVFFA-functionalized gold nanoclusters inhibit Aβ40 fibrillation, fibrils’ prolongation, and mature fibrils’ disaggregation. ACS Chem. Neurosci. 2019, 10, 4633–4642. [Google Scholar] [CrossRef]
- Austen, B.M.; Paleologou, K.E.; Ali, S.A.E.; Qureshi, M.M.; Allsop, D.; El-Agnaf, O.M.A. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer’s beta-amyloid peptide. Biochemistry 2008, 47, 1984–1992. [Google Scholar] [CrossRef] [PubMed]
- El-Agnaf, O.M.A.; Paleologou, K.E.; Greer, B.; Abogrein, A.M.; King, J.E.; Salem, S.A.; Fullwood, N.J.; Benson, F.E.; Hewitt, R.; Ford, K.J.; et al. A strategy for designing inhibitors of R-synuclein aggregation and toxicity as a novel treatment for Parkin. FASEB J. 2004, 18, 1315–1317. [Google Scholar] [CrossRef] [PubMed]
- Cruz, M.; Tusell, J.M.; Grillo-Bosch, D.; Albericio, F.; Serratosa, J.; Rabanal, F.; Giralt, E. Inhibition of β-amyloid toxicity by short peptides containing N-methyl amino acids. J. Pept. Res. 2004, 63, 324–328. [Google Scholar] [CrossRef] [PubMed]
- Chalifour, R.J.; Mclaughlin, R.W.; Lavoie, L.; Morissette, C.; Tremblay, N.; Boulé, M.; Sarazin, P.; Stéa, D.; Lacombe, D.; Tremblay, P.; et al. Stereoselective interactions of peptide inhibitors with the β-amyloid peptide. J. Biol. Chem. 2003, 278, 34874–34881. [Google Scholar] [CrossRef]
- Kokkoni, N.; Stott, K.; Amijee, H.; Mason, J.M.; Doig, A.J. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 2006, 45, 9906–9918. [Google Scholar] [CrossRef]
- Horsley, J.R.; Jovcevski, B.; Wegener, K.L.; Yu, J.; Pukala, T.L.; Abell, A.D. Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: A potential therapeutic strategy for Alzheimer’s disease. Biochem. J. 2020, 477, 2039–2054. [Google Scholar] [CrossRef]
- Faisal, A.; Kandel, N.; Tatulian, S.A. Effects of Aβ-derived peptide fragments on fibrillogenesis of Aβ. Sci. Rep. 2021, 11, 19262. [Google Scholar]
- Usmani, S.S.; Bedi, S.; Samuel, J.S.; Singh, S.; Kalra, S.; Kumar, P.; Ahuja, A.A.; Sharma, M.; Gautam, A.; Raghava, G.P.S. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 2017, 12, e0181748. [Google Scholar] [CrossRef]
- Zorzi, A.; Deyle, K.; Heinis, C. Cyclic peptide therapeutics: Past, present and future. Curr. Opin. Chem. Biol. 2017, 38, 24–29. [Google Scholar] [CrossRef]
- Arai, T.; Araya, T.; Sasaki, D.; Taniguchi, A.; Sato, T.; Sohma, Y.; Kanai, M. Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-beta based on a pharmacophore motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe-]. Angew. Chem. Int. Ed. 2014, 53, 8236–8239. [Google Scholar] [CrossRef]
- Bond, J.P.; Deverin, S.P.; Inouye, H.; el-Agnaf, O.M.; Teeter, M.M.; Kirschner, D.A. Assemblies of Alzheimer’s peptides Aβ25–35 and Aβ31–35: Reverse-turn conformation and side-chain interactions revealed by X-ray diffraction. J. Struct. Biol. 2003, 141, 156–170. [Google Scholar] [CrossRef] [PubMed]
- Liu, R.; McAllister, C.; Lyubchenko, Y.; Sierks, M.R. Residues 17–20 and 30–35 of beta-amyloid play critical roles in aggregation. J. Neurosci. Res. 2004, 75, 162–171. [Google Scholar] [CrossRef] [PubMed]
- Yan, X.Z.; Qiao, J.T.; Dou, Y.; Qiao, Z.D. Beta-amyloid peptide fragment 31–35 induces apoptosis in cultured cortical neurons. Neuroscience 1999, 92, 177–184. [Google Scholar] [CrossRef] [PubMed]
- Fulop, L.; Zarandi, M.; Datki, Z.; Soos, K.; Penke, B. β-amyloidderived pentapeptide RIIGLa inhibits Aβ1–42 aggregation and toxicity. Biochem. Biophys. Res. Commun. 2004, 324, 64–69. [Google Scholar] [CrossRef] [PubMed]
- Fradinger, E.A.; Monien, B.H.; Urbanc, B.; Lomakin, A.; Tan, M.; Li, H.; Spring, S.M.; Condron, M.M.; Cruz, L.; Xie, C.-W.; et al. C-terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 2008, 105, 14175–14180. [Google Scholar] [CrossRef]
- Cheng, P.-N.; Liu, C.; Zhao, M.; Eisenberg, D.; Nowick, J.S. Amyloid beta-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat. Chem. 2012, 4, 927–933. [Google Scholar] [CrossRef]
- Song, C.M.; Lim, S.J.; Tong, J.C. Recent advances in computer-aided drug design. Brief Bioinform. 2009, 10, 579–591. [Google Scholar] [CrossRef]
- Lu, J.; Cao, Q.; Wang, C.; Zheng, J.; Luo, F.; Xie, J.; Li, Y.; Ma, X.; He, L.; Eisenberg, D.; et al. Structure-based peptide inhibitor design of amyloid-β aggregation. Front. Mol. Neurosci. 2019, 12, 54. [Google Scholar] [CrossRef]
- Rosas-Valdéz, M.E.; Escalante, J.; Bustos-Jaimes, I.; Regla, I.; Boto, A. Synthesis and modification of the amyloid peptide sequence 37–42 of Aβ42 (AβPP): Efficient synthesis of N-methylated peptides, expanding the tools for peptide research. J. Mex. Chem. Soc. 2016, 60, 125–134. [Google Scholar] [CrossRef]
- Hopping, G.; Kellock, J.; Barnwal, R.P.; Law, P.; Bryers, J.; Varani, G.; Caughey, B.; Daggett, V. Designed alpha-sheet peptides inhibit amyloid formation by targeting toxic oligomers. eLife 2014, 3, e01681. [Google Scholar] [CrossRef] [PubMed]
- Prosswimmer, T.; Daggett, V. The role of α-sheet structure in amyloidogenesis: Characterization and implications. Open Biol. 2022, 12, 220261. [Google Scholar] [CrossRef] [PubMed]
- Xie, C.; Zhuang, X.-X.; Niu, Z.; Ai, R.; Lautrup, S.; Zheng, S.; Jiang, Y.; Han, R.; Gupta, T.S.; Cao, S.; et al. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow. Nat. Biomed. Eng. 2022, 6, 76–93. [Google Scholar] [CrossRef]
- Yang, H.; Mu, W.; Wei, D.; Zhang, Y.; Duan, Y.; Gao, J.; Gong, X.; Wang, H.; Wu, X.; Tao, H.; et al. A novel targeted and high-efficiency nanosystem for combinational therapy for Alzheimer’s disease. Adv. Sci. 2020, 7, 1902906. [Google Scholar] [CrossRef] [PubMed]
- Yuan, L.; Li, J.-Y. Exosomes in Parkinson’s disease: Current perspectives and future challenges. ACS Chem. Neurosci. 2019, 10, 963–972. [Google Scholar] [CrossRef] [PubMed]
- Yoon, J.; Lee, S.K.; Park, A.; Lee, J.; Jung, I.; Song, K.B.; Choi, E.J.; Kim, S.; Yu, J. Exosome from IFN-γ-primed induced pluripotent stem cell-derived mesenchymal stem cells improved skin inflammation and barrier function. Int. J. Mol. Sci. 2023, 24, 11635. [Google Scholar] [CrossRef]
- Saint-Pol, J.; Gosselet, F.; Duban-Deweer, S.; Pottiez, G.; Karamanos, Y. Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells 2020, 9, 851. [Google Scholar] [CrossRef]
- Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science 2020, 367, eaau6977. [Google Scholar] [CrossRef]
- Erak, M.; Bellmann-Sickert, K.; Els-Heindl, S.; Beck-Sickinger, A.G. Peptide chemistry toolbox—Transforming natural peptides into peptide therapeutics. Bioorg. Med. Chem. 2018, 26, 2759–2765. [Google Scholar] [CrossRef]
- Qvit, N.; Rubin, S.J.S.; Urban, T.J.; Mochly-Rosen, D.; Gross, E.R. Peptidomimetic therapeutics: Scientific approaches and opportunities. Drug Discov. Today 2017, 22, 454–462. [Google Scholar] [CrossRef] [PubMed]
- Vorherr, T. Modifying peptides to enhance permeability. Future Med. Chem. 2015, 7, 1009–1021. [Google Scholar] [CrossRef] [PubMed]
- Bhat, A.; Roberts, L.R.; Dwyer, J.J. Lead discovery and optimization strategies for peptide macrocycles. Eur. J. Med. Chem. 2015, 94, 471–479. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, C.; Shao, S.; Li, N.; Zhang, Z.; Zhang, H.; Liu, B. Advances in Alzheimer’s Disease-Associated Aβ Therapy Based on Peptide. Int. J. Mol. Sci. 2023, 24, 13110. https://doi.org/10.3390/ijms241713110
Wang C, Shao S, Li N, Zhang Z, Zhang H, Liu B. Advances in Alzheimer’s Disease-Associated Aβ Therapy Based on Peptide. International Journal of Molecular Sciences. 2023; 24(17):13110. https://doi.org/10.3390/ijms241713110
Chicago/Turabian StyleWang, Cunli, Shuai Shao, Na Li, Zhengyao Zhang, Hangyu Zhang, and Bo Liu. 2023. "Advances in Alzheimer’s Disease-Associated Aβ Therapy Based on Peptide" International Journal of Molecular Sciences 24, no. 17: 13110. https://doi.org/10.3390/ijms241713110